癌に対する免疫チェックポイント阻害剤療法における免疫関連の有害事象

Katie Liao¹, Emily Martin¹, Amy Body^2,3

¹Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.

Internal medicine journal

|August 26, 2025

まとめ

がん免疫療法は生存率を改善しますが,多くの患者で免疫関連の有害事象 (irAEs) を引き起こします. このレビューは,リウマチックな問題とその管理に焦点を当てて,iRAEを詳細に説明します.

科学分野:

腫瘍学
リウマトロジ
免疫学

背景:

ガンに対する免疫療法は過去10年間でガン治療に革命をもたらしました
がん生存率の改善により,免疫関連の有害事象 (irAEs) が増加し,患者の最大71. 5%が罹患した.
治療の中止をしばしば必要とする.

研究の目的:

発症率,病理生理学,診断,およびiraEsの管理に関する現在の文献を要約する.
具体的には,IRAのリウマチックな症状に焦点を当てます.
証拠の不足に対処し,改善された臨床ガイドラインの基盤を提供するためです.

主な方法:

免疫療法とIRAに関する既存の文献の体系的なレビュー.
発生率,メカニズム,診断基準,治療戦略に関するデータの分析
症例報告と専門家のコンセンサスに基づいたリウマチ性IRAの集中的なレビュー.

主要な成果:

高い割合の患者に発現し,重大な合併症を引き起こします.
リウマチ性IRAは,これらのイベントの顕著なサブセットであり,特別な注意が必要です.
現在の管理ガイドラインは限られた証拠に基づいているため,さらなる研究が必要である.

結論:

現代のがん治療における重要な課題です
患者のアウトカムにとって,特にリウマチック症状の最適の特定と管理は極めて重要です.
強力な証拠に基づいた iRAE管理のためのガイドラインを確立するには,さらなる研究が必要です.

キーワード:

免疫チェックポイント阻害剤免疫関連の有害事象免疫療法リウマチ学

さらに関連する動画

07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

539

06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

関連する概念動画

01:27

Tumor Immunotherapy

660

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

660

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

267

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

267

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

231

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

231

02:49

Cancer Therapies

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...